Ashley Zurawel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley Zurawel has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Anthony Sabulski
Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
1 shared publication- Heather Alva
11Division of Hematology, Oncology, Stem Cell Transplantation, and Regenerative Medicine, Department of Pediatrics, Lucile Packard Children’s Hospital at Stanford University, Palo Alto, CA
1 shared publication Janet L. Kwiatkowski
Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
1 shared publication- Jesse Yenchih Hsu
Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
1 shared publication Katelyn E. Heimbruch
Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
1 shared publication- Katherine T. Lind
Division of Bone Marrow Transplantation and Cellular Therapy, Children's Hospital Colorado, Aurora, CO
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3324-3334
Impact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders
Children with nonmalignant hematological disorders (NMHD) often require numerous red blood cell transfusions before hematopoietic stem cell transplantation (HSCT), leading to iron overload. Ferritin and liver iron concentration (LIC) are used to estimate the degree of iron overload to determine eligibility for HSCT, but neither marker has been definitively associated with poorer HSCT outcomes in pediatric cohorts. We conducted a multicenter retrospective cohort study using PEDSnet to examine the association between elevated pre-HSCT ferritin and LIC and HSCT outcomes and to evaluate iron reduction therapy after transplantation. A total of 580 patients with a pre-HSCT ferritin and 260 patients with a pre-HSCT LIC were studied. Patients with high pre-HSCT ferritin of >2500 ng/mL had decreased 3-year overall survival (adjusted hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.06-5.04). A sensitivity analysis demonstrated this trend only in patients with severe aplastic anemia (SAA). Elevated ferritin was associated with a markedly increased risk of bacteremia after HSCT in patients with SAA (HR, 3.33; 95% CI, 1.72-6.44). Elevated pre-HSCT LIC of >5 mg Fe/g dry weight was not associated with decreased survival, bacteremia, graft failure, or veno-occlusive disease (VOD). VOD was assessed only in patients undergoing busulfan-based transplantation. After transplantation, 63% of patients in the multicenter analysis had an elevated ferritin, whereas 68% had an elevated LIC. Chelation and phlebotomy were equally effective in reducing post-HSCT iron. These results challenge the use of LIC as the gold standard for iron-related risk stratification in HSCT. Further research into peri-HSCT iron management is necessary in an era of expanding availability of HSCT for NMHD.
- 13 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (10) , 3324-3334
Open AccessImpact of iron overload on hematopoietic stem cell transplantation in pediatric patients with nonmalignant hematological disorders
Children with nonmalignant hematological disorders (NMHD) often require numerous red blood cell transfusions before hematopoietic stem cell transplantation (HSCT), leading to iron overload. Ferritin and liver iron concentration (LIC) are used to estimate the degree of iron overload to determine eligibility for HSCT, but neither marker has been definitively associated with poorer HSCT outcomes in pediatric cohorts. We conducted a multicenter retrospective cohort study using PEDSnet to examine the association between elevated pre-HSCT ferritin and LIC and HSCT outcomes and to evaluate iron reduction therapy after transplantation. A total of 580 patients with a pre-HSCT ferritin and 260 patients with a pre-HSCT LIC were studied. Patients with high pre-HSCT ferritin of >2500 ng/mL had decreased 3-year overall survival (adjusted hazard ratio [HR], 2.31; 95% confidence interval [CI], 1.06-5.04). A sensitivity analysis demonstrated this trend only in patients with severe aplastic anemia (SAA). Elevated ferritin was associated with a markedly increased risk of bacteremia after HSCT in patients with SAA (HR, 3.33; 95% CI, 1.72-6.44). Elevated pre-HSCT LIC of >5 mg Fe/g dry weight was not associated with decreased survival, bacteremia, graft failure, or veno-occlusive disease (VOD). VOD was assessed only in patients undergoing busulfan-based transplantation. After transplantation, 63% of patients in the multicenter analysis had an elevated ferritin, whereas 68% had an elevated LIC. Chelation and phlebotomy were equally effective in reducing post-HSCT iron. These results challenge the use of LIC as the gold standard for iron-related risk stratification in HSCT. Further research into peri-HSCT iron management is necessary in an era of expanding availability of HSCT for NMHD.